| Literature DB >> 32109418 |
Erfan Aref-Eshghi1, Jennifer Kerkhof1, Victor P Pedro2, Mouna Barat-Houari3, Nathalie Ruiz-Pallares3, Jean-Christophe Andrau4, Didier Lacombe5, Julien Van-Gils5, Patricia Fergelot5, Christèle Dubourg6, Valerie Cormier-Daire7, Sophie Rondeau7, François Lecoquierre8, Pascale Saugier-Veber8, Gaël Nicolas8, Gaetan Lesca9, Nicolas Chatron9, Damien Sanlaville9, Antonio Vitobello10, Laurence Faivre11, Christel Thauvin-Robinet11, Frederic Laumonnier12, Martine Raynaud12, Mariëlle Alders13, Marcel Mannens13, Peter Henneman13, Raoul C Hennekam14, Guillaume Velasco15, Claire Francastel15, Damien Ulveling15, Andrea Ciolfi16, Simone Pizzi16, Marco Tartaglia16, Solveig Heide17, Delphine Héron17, Cyril Mignot17, Boris Keren17, Sandra Whalen18, Alexandra Afenjar18, Thierry Bienvenu19, Philippe M Campeau20, Justine Rousseau20, Michael A Levy21, Lauren Brick22, Mariya Kozenko22, Tugce B Balci23, Victoria Mok Siu23, Alan Stuart1, Mike Kadour24, Jennifer Masters24, Kyoko Takano25, Tjitske Kleefstra26, Nicole de Leeuw26, Michael Field27, Marie Shaw28, Jozef Gecz29, Peter J Ainsworth21, Hanxin Lin21, David I Rodenhiser30, Michael J Friez31, Matt Tedder31, Jennifer A Lee31, Barbara R DuPont31, Roger E Stevenson31, Steven A Skinner31, Charles E Schwartz31, David Genevieve32, Bekim Sadikovic33.
Abstract
Genetic syndromes frequently present with overlapping clinical features and inconclusive or ambiguous genetic findings which can confound accurate diagnosis and clinical management. An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called "episignatures"). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging patterns of overlap, as well as similarities and hierarchical relationships across these episignatures, to highlight their key features as they are related to genetic heterogeneity, dosage effect, unaffected carrier status, and incomplete penetrance. We demonstrate the necessity of multiclass modeling for accurate genetic variant classification and show how disease classification using a single episignature at a time can sometimes lead to classification errors in closely related episignatures. We demonstrate the utility of this tool in resolving ambiguous clinical cases and identification of previously undiagnosed cases through mass screening of a large cohort of subjects with developmental delays and congenital anomalies. This study more than doubles the number of published syndromes with DNA methylation episignatures and, most significantly, opens new avenues for accurate diagnosis and clinical assessment in individuals affected by these disorders.Entities:
Keywords: DNA methylation; EpiSign; VUS classification; episignature; molecular diagnostics; uncertain clinical cases
Mesh:
Year: 2020 PMID: 32109418 PMCID: PMC7058829 DOI: 10.1016/j.ajhg.2020.01.019
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025